Stockreport
Investors Pile Into Amgen in Search of Next Obesity Drug Payout [BNN Bloomberg (Canada)]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
The shares surged 12% Friday, the biggest one-day jump for Amgen in nearly 15 years, fueled by fresh optimism about the company's future in the lucrative market for weight-loss drugs after upbeat commentary from the chief executive officer. Although it could take years for a drug to come to market, investors who are looking for new ways trade into the hype are betting that the Amgen's anti-obesity entrant, MariTide, could compete against current blockbusters. Wall Street's enthusiasm for medicines tied to weight loss has supercharged Lilly, which is now the biggest health-care company in the world by market value. Likewise, Novo is the most valuable listed company in Europe and other runners up have also notched healthy gains. Read more: Here Are the Obesity Drug Hopefuls Vying to Unseat Lilly, Novo “There's a clear enthusiasm to get more things on market and try to have something that is differentiated so that even if you are three or four years behind getting to market, you c
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- FDA Roundup: May 17, 2024 [Yahoo! Finance][Yahoo! Finance]
- Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance][Yahoo! Finance]
- U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)][Globe and Mail, The]
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER[PR Newswire]
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times][The New York Times]
- More
AMGN
SEC Filings
SEC Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More